Physician profile
Minh Mach
NPI 1831298736
$558,784.26
in general payments reported to CMS, 2019-2025
55 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $71K · 2021: $81K · 2022: $114K · 2023: $116K · 2024: $73K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $219K · Food and Beverage: $16K · Travel and Lodging: $6,746 · Consulting Fee: $2,600 · Gift: $59.40 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $218,925.00 |
| Food and Beverage | $16,026.34 |
| Travel and Lodging | $6,746.27 |
| Consulting Fee | $2,600.00 |
| Gift | $59.40 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $398,639.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52,578.72 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $39,272.72 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $32,033.30 | 2019-2025 | |
| Mannkind Corporation | $12,592.22 | 2019-2025 | V-Go, Afrezza |
| Medtronic, INC. | $3,967.45 | 2021-2025 | Minimed 780g |
| Ibsa Pharma INC. | $3,468.64 | 2019-2025 | Tirosint, Licart, Flector |
| Novo Nordisk INC | $2,807.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $1,886.43 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $1,746.37 | 2019-2025 | Freestyle Libre 3, Eterna |
| Insulet Corporation | $982.16 | 2019-2025 | Omnipod |
| Radius Health, INC. | $668.43 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $645.83 | 2019-2022 | |
| Abbvie INC. | $636.95 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $599.38 | 2019-2025 | Contrave, Nexlizet, Nexletol |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $596.17 | 2019-2025 | Tepezza, Repatha, Repatha |
| Alexion Pharmaceuticals, INC. | $502.56 | 2021-2025 | Strensiq |
| Lexicon Pharmaceuticals, INC. | $428.39 | 2023-2024 | Inpefa |
| Xeris Pharmaceuticals, INC. | $423.50 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $418.33 | 2022-2025 | |
| Embecta Corp. | $348.54 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Medtronic Minimed, INC. | $346.04 | 2019-2020 | |
| Zealand Pharma US, INC. | $328.18 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $310.11 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $287.22 | 2021-2025 | |
| Esperion Therapeutics, INC. | $229.01 | 2020-2024 | Nexletol |
| Corcept Therapeutics | $212.93 | 2020-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $192.74 | 2023-2025 | |
| Shire North American Group INC | $142.36 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $141.21 | 2023-2025 | Baqsimi |
| Acerus Pharmaceuticals Corporation | $131.17 | 2020-2022 | |
| Antares Pharma, INC. | $119.93 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Lifescan, INC. | $96.97 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $89.33 | 2022-2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $88.43 | 2019-2021 | |
| Kyowa Kirin, INC. | $77.84 | 2023-2025 | Crysvita |
| Ionis Pharmaceuticals, INC. | $77.10 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $76.28 | 2025 | Rezdiffra |
| Pfizer INC. | $74.96 | 2023 | |
| Bigfoot Biomedical INC | $64.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.04 | 2019-2020 | |
| Valeritas, INC. | $56.78 | 2019 | |
| Becton, Dickinson and Company | $53.43 | 2022 | |
| Eisai INC. | $46.32 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $42.30 | 2019 | |
| Alfasigma USA, INC. | $38.40 | 2020-2021 | |
| Sequel Med Tech, LLC | $34.49 | 2025 | Twiist |
| Halozyme INC | $24.56 | 2023 | |
| Companion Medical, INC. | $23.59 | 2020 | |
| Vistapharm, INC. | $22.76 | 2021 | |
| Vivus LLC | $21.60 | 2022 | |
| Recordati_rare_diseases_inc. | $15.47 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.94 | 2023 | Adthyza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Mach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.